Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide.

Findings seen in patients with posterior circulation stroke and with no planned thrombectomy who received alteplase 4.5 to 24 hours after stroke onset.

GLP-1 receptor agonist prescriptions increased significantly during study period across all categories of BMI, in dose-response manner.

The delay dovetails with moves by Republican lawmakers in at least 7 states to ban or limit mRNA vaccines. Some, according to KFF Health News, are also pressing regulators to revoke federal approval ...

The Food and Drug Administration (FDA) has cleared the Visby Medical Women’s Sexual Health Test for use at home to test for ...

The Food and Drug Administration (FDA) has approved Uplizna ® (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease (IgG4-RD) in adult patients.

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

The FDA is expected to decide on treatments for COPD, psoriasis, rare neuroendocrine tumors, and a next-generation COVID-19 vaccine.

BIIB080 is an antisense oligonucleotide therapy designed to target microtubule-associated protein tau mRNA and reduce the production of tau.

Detailed study results will be presented at an upcoming medical meeting and submitted to health authorities later this year to expand Palynziq’s label to include adolescents.

The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...